Global Achalasia Cardia Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Achalasia Cardia Market Analysis

The achalasia cardia market is experiencing significant growth driven by advancements in diagnostic and treatment options for this esophageal motility disorder, which affects the ability of the esophagus to move food into the stomach. Innovations in endoscopic techniques, such as peroral endoscopic myotomy (POEM), have emerged as minimally invasive treatment alternatives, allowing for effective symptom relief with reduced recovery times compared to traditional surgical methods. Additionally, advancements in high-resolution esophageal topography (HREPT) provide enhanced diagnostic accuracy, enabling earlier detection and intervention, which is crucial for improving patient outcomes. The incorporation of novel therapies, including injectable botulinum toxin and pneumatic balloon dilation, further expands the treatment landscape, offering various options tailored to patient needs. As awareness of achalasia increases among healthcare professionals and patients, the market for achalasia treatments is projected to grow, reflecting the rising demand for effective management strategies and improved quality of life for those affected by this condition.

Achalasia Cardia Market Size

The global achalasia cardia market size was valued at USD 522.16 million in 2024 and is projected to reach USD 1,169.09 million by 2032, with a CAGR of 10.60% during the forecast period of 2025 to 2032. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Achalasia Cardia Market Trends

“Growing Adoption of Minimally Invasive Treatment Options”

One notable trend in the achalasia cardia market is the growing adoption of minimally invasive treatment options, which significantly improve patient outcomes and reduce recovery times. Techniques such as peroral endoscopic myotomy (POEM) have gained traction due to their ability to effectively relieve symptoms by cutting the muscle fibers at the lower esophageal sphincter without the need for large incisions.  Additionally, advancements in diagnostic tools such as high-resolution manometry (HRM) allow for more accurate assessments of esophageal function, facilitating timely intervention. This shift towards less invasive approaches enhances the patient experience and encourages healthcare providers to consider these options as first-line treatments. As a result, the achalasia cardia market is witnessing increased demand for innovative procedures that prioritize patient comfort and efficiency in care delivery.

Report Scope and Achalasia Cardia Market Segmentation    

Achalasia Cardia Market Definition

Achalasia cardia is a rare esophageal disorder characterized by the inability of the lower esophageal sphincter (LES) to relax properly during swallowing, leading to difficulty in food and liquid passage from the esophagus into the stomach. This condition results from the degeneration of nerve cells in the esophagus, which disrupts normal muscle function and causes symptoms such as chest pain, regurgitation, dysphagia (difficulty swallowing), and weight loss. As the esophagus becomes increasingly dilated and dysfunctional over time, it can lead to complications such as esophagitis and aspiration pneumonia. Achalasia cardia typically requires medical intervention, which may include medications, balloon dilation, or surgical procedures to alleviate symptoms and improve the patient’s quality of life.

Achalasia Cardia Market Dynamics

Drivers

• Rising Incidence of Achalasia

The rising incidence of achalasia is becoming increasingly evident, with studies suggesting that its prevalence ranges from 0.5 to 1.6 cases per 100,000 individuals annually in the U.S. and Europe. This increase is attributed to a combination of genetic predispositions and environmental factors, including viral infections that may trigger autoimmune responses leading to the disorder. For instance, a recent analysis revealed a notable uptick in diagnoses, with a 30% rise in cases over the past decade, highlighting the growing awareness of achalasia among both patients and healthcare providers. As individuals become more educated about the symptoms, such as difficulty swallowing and chest pain, they are more likely to seek medical help. This heightened demand for effective diagnostic tools and treatment options, including surgical interventions and pharmacological therapies, is driving market growth for achalasia cardia treatments. The combination of increasing incidence rates and improved awareness underscores the urgency for enhanced healthcare solutions in this area, making it a significant market driver.

• Increasing Healthcare Expenditure

Increasing healthcare expenditure plays a pivotal role in enhancing access to diagnostic and treatment options for achalasia, particularly in developing regions. For instance, countries such as India and Brazil have seen substantial investments in healthcare infrastructure, leading to the establishment of specialized centers for gastrointestinal disorders. The World Health Organization reported that many developing countries have increased their healthcare budgets by over 10% annually, focusing on expanding access to essential medical services. This evolution of healthcare systems prioritizes patient care and education, resulting in improved awareness and diagnosis of conditions such as achalasia. As healthcare providers incorporate advanced technologies and treatment methods, patients gain better access to effective therapies such as pneumatic balloon dilation and laparoscopic Heller myotomy. Consequently, this rise in healthcare expenditure is a significant market driver, fostering a conducive environment for the growth of achalasia treatment options as more patients seek timely interventions.

Opportunities

• Technological innovations in diagnosis and treatment

Technological innovations in the field of achalasia diagnosis and treatment present a significant market opportunity by enhancing the accuracy and efficiency of patient management. The introduction of advanced diagnostic tools, such as high-resolution esophageal manometry, allows for precise measurement of esophageal muscle contractions, enabling healthcare providers to diagnose achalasia more accurately. For instance, studies have shown that the use of high-resolution manometry improves diagnostic accuracy rates by over 30% compared to traditional methods. Additionally, cutting-edge endoscopic techniques, including minimally invasive balloon dilation, are revolutionizing treatment options, resulting in quicker recovery times and improved patient satisfaction. As healthcare facilities increasingly recognize the benefits of these advanced technologies, their adoption is likely to rise, further driving market growth. This integration of innovative diagnostic and treatment tools enhances patient outcomes and fosters a more robust ecosystem for achalasia care, positioning technological advancements as a key opportunity in the market.

• Growing Awareness of Achalasia Symptoms

The growing awareness of achalasia symptoms among both healthcare professionals and patients represents a significant market opportunity, as it directly contributes to improved diagnosis rates and timely medical intervention. Educational initiatives and campaigns aimed at highlighting the disorder's signs, such as difficulty swallowing and regurgitation, have led to increased recognition among patients, prompting them to seek medical help sooner. For instance, a study published in the American Journal of Gastroenterology found that patients who were informed about achalasia were 40% more likely to seek treatment within 6 months of experiencing symptoms compared to those who were unaware. This heightened awareness facilitates earlier diagnosis and drives demand for treatment options, including botulinum toxin injections and surgical procedures. As more individuals become informed about achalasia, healthcare providers are better equipped to respond to their needs, thus expanding the overall market for achalasia treatments and improving patient outcomes.

Restraints/Challenges

• High Costs Associated with Achalasia Cardia Treatment

High treatment costs represent a significant challenge in the achalasia cardia market, impacting patient access to necessary care. The expenses associated with diagnosing achalasia, including endoscopic evaluations and imaging studies, can be substantial. Furthermore, surgical interventions, such as laparoscopic Heller myotomy, and subsequent long-term follow-up care add to the financial burden. For instance, the average cost of surgical treatment can exceed several thousand dollars, a sum that may be unmanageable for patients lacking adequate health insurance. This financial strain can deter individuals from seeking timely treatment or adhering to recommended follow-up care, potentially leading to deteriorating health outcomes. Consequently, high treatment costs restrict access for many patients and hinder overall market growth by limiting the patient population that can afford these essential interventions.

• Complex Regulatory Frameworks

Regulatory challenges present a significant hurdle in the achalasia cardia market, particularly for new treatment modalities and devices. The process of obtaining regulatory approval involves navigating intricate pathways that require extensive documentation, clinical trials, and compliance with stringent safety and efficacy standards. For instance, a small start-up developing an innovative endoscopic treatment for achalasia may face delays of several years while awaiting regulatory clearance from agencies such as the FDA or EMA. This protracted timeline can be particularly burdensome for smaller companies with limited resources, as the costs associated with clinical trials, regulatory submissions, and potential modifications can quickly accumulate. Consequently, the complexity and duration of the regulatory process can stifle innovation and deter companies from entering the market, thereby limiting the availability of novel treatment options for patients suffering from achalasia.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Achalasia Cardia Market Scope

The market is segmented on the basis of disease type, diagnosis, treatment, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Type I
• Type II
• Type III

Diagnosis

• High Resolution Oesophageal Topography
• Endoscopy

Treatment

• Botulinum Toxin
• Pneumatic Balloon Dilation
• Laparoscopic Heller Myotomy

End Users

• Clinics
• Hospitals
• Diagnostic Centers
• Others

Distribution Channel

• Direct Tenders
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Achalasia Cardia Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, disease type, diagnosis, treatment, end users, and distribution channel as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North American holds the largest share in the global achalasia cardia market, driven by expanding research and development efforts and continuous technological advancements. Increasing investments in innovative treatments and the presence of well-established healthcare infrastructure further contribute to the market’s growth in this region.

Asia-Pacific is projected to hold a significant share in the global achalasia cardia market, supported by growing government focus on public health initiatives and an increase in funding aimed at strengthening the pharmaceutical sector. Expanding healthcare infrastructure and rising awareness about achalasia treatment options are also driving market growth. Furthermore, supportive regulatory policies and investment in medical research enhance the region’s potential in the market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Achalasia Cardia Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Achalasia Cardia Market Leaders Operating in the Market Are:

• AbbVie Inc. (U.S.)
• Ipsen Pharma (France)
• Merz Pharma (Germany)
• Medytox (South Korea)
• REVANCE Therapeutics (U.S.)
• Boston Scientific Corporation (U.S.)
• Cook (U.S.)
• Cardinal Health (U.S.)
• Medical Devices Business Services, Inc. (U.S.)
• Hospiinz (India)
• Surgical Innovations (U.K.)
• Evolus, Inc. (U.S.)
• Medorah Meditek Pvt. Ltd. (India)
• STERIS (U.S.)
• PENTAX Medical (Japan)
• XION (Germany)
• Aohua Endoscopy Co., Ltd. (China)
• Laborie (Canada)
• Sumitomo Bakelite Co., Ltd. (Japan)
• Medtronic (U.S.)

SKU-61209